Actively Recruiting
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Led by Elgan Pharma Ltd. · Updated on 2026-01-23
360
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.
CONDITIONS
Official Title
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female preterm infant born between 26 and up to 32 weeks gestation with gestational age confirmed by maternal dates and/or early antenatal ultrasound within ±2 weeks
- Birth weight of at least 500 grams
- Singleton or twin birth
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Laniado Hospital
Netanya, Israel, 4244916
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here